Last updated: April 23, 2026
What is CN1571670 and what does the patent claim cover?
CN1571670 is a Chinese drug patent publication identified as “CN1571670” in the China patent record. The record for this specific identifier should be used to determine the exact drug name/INN, salt form, dosage form, and therapeutic use, because Chinese drug patents often have multiple related documents (same family, different claims, and different prosecution outcomes).
However, producing a complete and accurate scope-and-claims analysis requires the full text (claims and description) of CN1571670 and the office actions/independent claim set that correspond to that exact publication. Without the claim text, any “scope” summary would be speculative.
What are the independent claim boundaries in CN1571670?
A defensible scope analysis depends on the claim architecture:
- Whether CN1571670 uses compound Markush language (substituent ranges, formulae, and defined variables)
- Whether it claims specific chemical entities (exact structures) vs classes
- Whether it claims formulations (dosage forms, excipients, particle size, polymorph)
- Whether it claims methods of treatment (specific diseases, dosing regimens)
- Whether it claims processes (manufacturing steps, intermediates)
A complete claim boundary mapping is not possible without the actual claim text for CN1571670.
What dependent claims narrow or expand scope?
Dependent claims in China drug filings typically narrow scope through one or more of:
- Salt selection (counterions)
- Polymorph/solid-state form
- Dosage (mg range, frequency)
- Treatment endpoint (patient population or indication)
- Formulation parameters (release profile, stability, excipients)
A claim-by-claim narrowing map also requires the full dependent claim set.
How does CN1571670 sit in the broader China patent landscape?
A landscape analysis that is investment-grade normally covers:
- Same-molecule family in China: priority chain, continuation, divisional/substantive amendments
- Secondary patents: solid form, salts, polymorphs, composites, formulation, device delivery, method-of-use
- Competitor positioning: other applicants’ early filings that target generic entry or carve-outs
- Regulatory link: National Medical Products Administration (NMPA) status and listing patterns (where patent linkage applies)
- Enforcement posture: common litigation patterns in China (infringement theories and claim selection)
To execute this for CN1571670, the drug identity and claim scope must be known precisely. The “CN1571670” identifier alone does not provide enough detail to reliably map the family, equivalents, or competitor filings without the underlying publication text.
Landmark claim concepts that must be verified for CN1571670
Below are the specific claim elements that determine competitive freedom-to-operate in China for drug patents. For CN1571670, each must be confirmed directly from the claims:
- Molecular definition: exact structure vs Markush ranges (formula variables, substituent definitions, exclusions).
- Salt/form: explicit salt list or counterion genus; polymorph claims.
- Use: therapeutic indication and whether it is limited to a disease entity or covers broader “treatment of” language.
- Dosage regimen: whether the claims include mg range, daily dose, frequency, or duration.
- Formulation: dosage form claims (tablets, capsules, injection), release mechanism, excipients, particle size, stability.
- Process: whether the claims include manufacturing steps that could affect generic manufacturing.
Without verifying these from CN1571670’s claim text, no accurate scope or landscape can be produced.
What does an actionable “CN1571670 landscape” deliver?
A complete deliverable for business decisions usually includes:
- Claim chart framework: mapping key claim terms to the company’s candidate molecule/formulation
- Patent family graph: priority date, jurisdictions, China grant/publication status
- Design-around catalog: which claim terms create barriers (salt/polymorph, indication, formulation)
- Generic risk: likelihood of infringement under literal vs doctrine-of-equivalents theories in China
- FTO timing: effective dates, term, and likely invalidation routes based on known art
Executing this for CN1571670 requires the exact identity of the drug and the textual claim set.
Key Takeaways
- CN1571670’s scope and claim boundaries cannot be determined accurately without the patent’s published full text and claim set for that exact document.
- A defensible China landscape requires confirmation of CN1571670’s drug identity, salt/polymorph/formulation status, and indication/dosage wording in the claims.
- An investment-grade analysis for CN1571670 must include a claim chart, a family graph, and a competitor mapping grounded in the actual claim language.
FAQs
1) Is CN1571670 a compound patent or a formulation/method-of-use patent?
Not determinable from the identifier alone; must be verified in the CN1571670 claim text.
2) Does CN1571670 claim a specific salt or polymorph?
Not determinable without reviewing the dependent and independent claims in CN1571670.
3) What indication or therapeutic use does CN1571670 cover?
Not determinable without the claims’ “use” language.
4) How does CN1571670 affect generic entry in China?
That depends on what is claimed (compound vs salt vs polymorph vs method vs formulation) and whether competitors can design around claim elements; requires the claim set.
5) Can CN1571670 be enforced broadly against different manufacturers?
Enforceability breadth in China depends on claim construction from the exact claim language and the proof needed for infringement; this cannot be stated without the claims.
References
[1] CN1571670 (China patent publication record).
